124 related articles for article (PubMed ID: 38601153)
1. IL-33-dependent NF-κB activation inhibits apoptosis and drives chemoresistance in acute myeloid leukemia.
Yan M; Chen X; Ye Q; Li H; Zhang L; Wang Y
Cytokine; 2024 Jun; 180():156672. PubMed ID: 38852492
[TBL] [Abstract][Full Text] [Related]
2. Linking Cancer Metabolism to DNA Repair and Accelerated Senescence.
Efimova EV; Takahashi S; Shamsi NA; Wu D; Labay E; Ulanovskaya OA; Weichselbaum RR; Kozmin SA; Kron SJ
Mol Cancer Res; 2016 Feb; 14(2):173-84. PubMed ID: 26538285
[TBL] [Abstract][Full Text] [Related]
3. Proteinase 3 depletion attenuates leukemia by promoting myeloid differentiation.
Liu H; Sun L; Zhao H; Zhao Z; Zhang S; Jiang S; Cheng T; Wang X; Wang T; Shao Y; Zhu H; Han H; Cao Y; Jiang E; Cao Y; Xu Y
Cell Death Differ; 2024 Jun; 31(6):697-710. PubMed ID: 38589495
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation and immune cell signaling: A review of known and a preview of unknown.
Ramakrishnan P
J Biol Chem; 2024 May; 300(6):107349. PubMed ID: 38718861
[TBL] [Abstract][Full Text] [Related]
5. Lack of Altered BECN1 Gene Expression in Iranian Patients with Acute Myeloid Leukemia.
Keyvan L; Bidoki SK; Zare Abdollahi D; Mansouri N; Hashemi M; Mortazavi Tabatabaei S; Fardmanesh H; Meimandi M; Ayatollahi SM; Jalaeikhoo H; Movafagh A
Asian Pac J Cancer Prev; 2016 Dec; 17(12):5173-5177. PubMed ID: 28124883
[TBL] [Abstract][Full Text] [Related]
6. Too sweet to resist: Control of immune cell function by O-GlcNAcylation.
de Jesus T; Shukla S; Ramakrishnan P
Cell Immunol; 2018 Nov; 333():85-92. PubMed ID: 29887419
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers.
Spaner DE
Front Immunol; 2021; 12():772304. PubMed ID: 34868034
[TBL] [Abstract][Full Text] [Related]
8. Single cell and bulk RNA expression analyses identify enhanced hexosamine biosynthetic pathway and O-GlcNAcylation in acute myeloid leukemia blasts and stem cells.
Schauner R; Cress J; Hong C; Wald D; Ramakrishnan P
Front Immunol; 2024; 15():1327405. PubMed ID: 38601153
[TBL] [Abstract][Full Text] [Related]
9. Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death.
Asthana A; Ramakrishnan P; Vicioso Y; Zhang K; Parameswaran R
Mol Cancer Ther; 2018 Oct; 17(10):2226-2237. PubMed ID: 30082471
[TBL] [Abstract][Full Text] [Related]
10. OGT-mediated O-GlcNAcylation promotes NF-κB activation and inflammation in acute pancreatitis.
Zhang D; Cai Y; Chen M; Gao L; Shen Y; Huang Z
Inflamm Res; 2015 Dec; 64(12):943-52. PubMed ID: 26407569
[TBL] [Abstract][Full Text] [Related]
11. Hexosamine Biosynthetic Pathway-Derived O-GlcNAcylation Is Critical for RANKL-Mediated Osteoclast Differentiation.
Kim MJ; Kim HS; Lee S; Min KY; Choi WS; You JS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445596
[TBL] [Abstract][Full Text] [Related]
12. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
13. Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation.
Hu J; Gao Q; Yang Y; Xia J; Zhang W; Chen Y; Zhou Z; Chang L; Hu Y; Zhou H; Liang L; Li X; Long Q; Wang K; Huang A; Tang N
Theranostics; 2021; 11(2):805-823. PubMed ID: 33391506
[No Abstract] [Full Text] [Related]
14. FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.
Abdel-Aziz AK; Dokla EME; Saadeldin MK
Crit Rev Oncol Hematol; 2023 Nov; 191():104139. PubMed ID: 37717880
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of O-GlcNAcase Inhibits Hematopoietic and Leukemic Stem Cell Self-Renewal and Drives Dendritic Cell Differentiation via STAT3/5 Signaling.
Luanpitpong S; Rodboon N; Samart P; Janan M; Klaihmon P; Lorthongpanich C; U-Pratya Y; Issaragrisil S
Stem Cells; 2022 Dec; 40(12):1078-1093. PubMed ID: 36124999
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
